New River Pharmaceuticals Strikes Deal With UK Company

New River Pharmaceuticals announced today a drug-development agreement that positions the small Radford company to receive a share of the U.S. profits of its planned treatment for attention-deficit/hyperactivity disorder and up to $500 million from partner Shire Pharmaceuticals Group if the product sells well. In a 10-paragraph press release, New River and UK-based Shire announced the signing of a collaboration agreement to jointly develop, manufacture, market and sell New River's drug known in the laboratory as NRP104.

The Roanoke Times (http://www.roanoke.com/news/roanoke/17775.html)